Repertoire Immune Medicines shared a post on LinkedIn:
“We are pleased to announce our collaboration with Eli Lilly and Company to discover new T cell-targeted medicines for autoimmune diseases. Our shared goal is to develop tolerizing therapies that reset the immune system and provide durable disease remission for patients.”
Robert Andtbacka, Chief Medical Officer at Repertoire Immune Medicines, shared this post, adding:
“Proud moment for our team at Repertoire. We’re partnering with Lilly to develop tolerizing therapies for autoimmune disease, building on our deep expertise in decoding T cell–epitope biology and translating those insights into medicines.”
More posts about Eli Lilly and Company.